A decrease in p-p38 MAPK levels may be the mechanism by which CXCR4 antagonists disrupt the chemotaxis of FLT3-ITD-expressing AML cells toward CXCL12. The gene discussed is CXCL12; the disease is acute myeloid leukemia.